Current:Home > BackModerna-Merck vaccine cuts odds of skin cancer recurrence in half, study finds-DB Wealth Institute B2 Expert Reviews
Moderna-Merck vaccine cuts odds of skin cancer recurrence in half, study finds
View Date:2024-12-23 19:21:28
A vaccine shows promising results in treating the most deadly form of skin cancer, Moderna and Merck announced on Thursday.
Those with severe melanomas who received the vaccine and Merck's cancer drug Keytruda were 49% less likely to die or have their cancer come back after three years than those who were given only Keytruda, the biotech companies said in a news release.
The findings are based on an ongoing randomized trial involving 157 patients with high-risk stage III/IV melanoma who first had surgery to completely remove cancerous growths. Patients received one milligram of the mRNA vaccine every three weeks for nine doses, and 200 milligrams of Keytruda every three weeks for about a year versus Keytruda alone for approximately a year.
The companies have begun Phase 3 trials of mRNA-4157 with Keytruda for people with stage III and IV melanoma. The Food and Drug Administration earlier this year designated the treatment as a breakthrough therapy in order to expedite the development and review of drugs meant to treat life-threatening diseases.
"We look forward to sharing these data with people impacted by the disease and the broader scientific community," Kyle Holen, M.D., Moderna's senior vice president and head of development, therapeutics and oncology, stated.
The results are a vindication of sorts for Moderna's strategy to develop new uses for messenger RNA technology used in its COVID-19 vaccine. Cambridge, Massachusetts-based Moderna said in November it anticipates a steep decline in revenue next year, fueling worries about its capacity to finance multiple product launches planned for 2024 and 2025.
Skin cancer is the most common form of cancer, with melanoma accounting for only about 1% of skin cancer cases in the U.S. That said, it causes a large majority of skin cancer deaths, according to the American Cancer Society. It estimates about 97,610 new melanomas will be diagnosed in the U.S. this year, resulting in 7,990 deaths.
Moderna's stock has cratered this year, falling 50%. On Thursday, its shares shot up 12% in mid-day trading to $87.93.
Rahway, New Jersey-based Merck shares treaded water, down 0.2% at $106.16.
- In:
- Moderna
- Cancer
- Merck
Kate Gibson is a reporter for CBS MoneyWatch in New York.
veryGood! (753)
Related
- Messi breaks silence on Inter Miami's playoff exit. What's next for his time in the US?
- Tom Brady Shares His and Ex Gisele Bundchen's Parenting Game Plan
- Al Pacino and More Famous Men Who Had Children Later in Life
- Microsoft slashes 10,000 jobs, the latest in a wave of layoffs
- Nevada trial set for ‘Dances with Wolves’ actor in newly-revived sex abuse case
- Anthropologie's Epic 40% Off Sale Has the Chicest Summer Hosting Essentials
- Cuomo’s New Climate Change Plan is Ambitious but Short on Money
- If You Hate Camping, These 15 Products Will Make the Experience So Much Easier
- Man gets a life sentence in the shotgun death of a New Mexico police officer
- Glasgow Climate Talks Are, in Many Ways, ‘Harder Than Paris’
Ranking
- Monument erected in Tulsa for victims of 1921 Race Massacre
- National Splurge Day: Shop 10 Ways To Treat Yourself on Any Budget
- Britney Spears' memoir The Woman in Me gets release date
- Colorado woman dies after 500-foot fall while climbing at Rocky Mountain National Park
- Brian Austin Green’s Fiancée Sharna Burgess Celebrates Megan Fox’s Pregnancy News
- New York City nurses end strike after reaching a tentative agreement
- Can China save its economy - and ours?
- Squid Game Season 2 Gets Ready for the Games to Begin With New Stars and Details
Recommendation
-
NFL power rankings Week 11: Steelers, Eagles enjoying stealthy rises
-
Inside Clean Energy: Coronavirus May Mean Halt to Global Solar Gains—For Now
-
Biden Heads for Glasgow Climate Talks with High Ambitions, but Minus the Full Slate of Climate Policies He’d Hoped
-
Did AI write this headline?
-
RHOP's Candiace Dillard Bassett Gives Birth, Shares First Photos of Baby Boy
-
The Pence-Harris Showdown Came up Well Short of an Actual ‘Debate’ on Climate Change
-
T-Mobile says breach exposed personal data of 37 million customers
-
Zendaya Feeds Tom Holland Ice Cream on Romantic London Stroll, Proving They’re the Coolest Couple